Insmed Inc Appoints Paul Hudson and Utpal Koppikar to Board

By Greg Peters • Tuesday, October 20 10:51 • Permanent Link

Insmed added two new independent directors to its board on Oct. 20, appointing Paul Hudson and Utpal Koppikar effective immediately.

Hudson, who most recently served as chief executive officer of Sanofi from September 2019 through February 2026, previously led Novartis Pharmaceuticals from 2016 to 2019 and held senior roles at AstraZeneca, including president of AstraZeneca U.S. and executive vice president for North America. His career also includes sales and marketing roles at Schering-Plough, GlaxoSmithKline UK and Sanofi-Synthélabo UK.

Koppikar has been chief financial officer of Verily Health since April 2023, overseeing finance, real estate and workplace services, and corporate development. Before that, he was executive vice president and CFO at Atara Biotherapeutics from 2018 to 2023 and previously held senior financial leadership roles at Gilead Sciences and Amgen. He also sits on the board of C4 Therapeutics.

Insmed said the appointments expand its board with experience in global biopharma leadership, commercial strategy and financial management as it continues to advance its pipeline and commercial business. As a result of these announcements, the company's shares have moved -1.02% on the market, and are now trading at a price of $95.29. For the full picture, make sure to review INSMED Inc's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.